Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone

BACKGROUND: All the peroxisome proliferator activated receptors (PPARs) are found to be expressed in bone cells. The PPARγ agonist rosiglitazone has been shown to decrease bone mass in mice and thiazolidinediones (TZDs) have recently been found to increase bone loss and fracture risk in humans treat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Syversen, Unni, Stunes, Astrid K, Gustafsson, Björn I, Obrant, Karl J, Nordsletten, Lars, Berge, Rolf, Thommesen, Liv, Reseland, Janne E
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2009
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2678137/
https://ncbi.nlm.nih.gov/pubmed/19331671
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1472-6823-9-10
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge